Center for Arthritis & Autoimmune Diseases

- Year 1
- Year 2
- Year 3

Department Home

Basic & Clinical Research

For Rheumatoid Arthritis and Osteoarthritis:

A Multicenter, Double-Blind, Parallel Group Study Comparing the Incidence of Clinically Significant Upper GI Adverse Events Associated with Celecoxib (SC-58635) 400 mg bid to that of Ibuprofen 800 mg tid in Patients with OA or RA

***Opened to any type of OA (hip, knee, spine, shoulder, foot etc.) or RA (RF +/ RF-)***

Inclusion Criteria:

*Documented Diagnosis of RA or OA for at least 3 months requiring chronic NSAID use

*Must be willing to participate for the duration of the study (52 weeks)

Exclusion Criteria:

*No active GI disease

*No history of gastric or duodenal surgery other than simple oversew of an ulcer or perforation

*NO regular use of anti-ulcer medications (H-2 antagonists, proton pump inhibitors, sucralfate and misoprostol) Short-term use of antacids is permitted.

*NO active malignancy (history of malignancy acceptable if no evidence of recurrence in 5 years or greater)

*NO hypersensitivity to COX-2 inhibitors, sulfonamides, or ibuprofen

***Patients will be paid $150 for participation***

Eileen McCullagh, RN, CCRC
Voicemail: 212-598-6613
Beeper: (917) 218-5449
E-mail: Eileen.McCullagh@Med.NYU.Edu